Celldex Therapeutics CLDX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$283.65M-58.6% | -$258.76M-63.9% | -$224.53M-45.7% | -$199.61M-32.9% | -$178.85M-23.5% | ||
| $3.37M+3.0% | $3.38M+6.4% | $3.38M+8.5% | $3.35M+8.0% | $3.27M+6.9% | ||
| $35.42M-2.6% | $36.22M+5.8% | $37.09M+17.1% | $37.91M+29.9% | $36.36M+35.9% | ||
| -$222.16M-29.5% | -$210.95M-33.7% | -$179.48M-13.7% | -$186.19M-53.3% | -$171.51M-43.7% | ||
| $4.09M+122% | $2.71M+41.4% | $2.19M+19.7% | $2.29M+59.2% | $1.84M+16.7% | ||
| $238.24M— | $209.07M— | —— | —— | —— | ||
| $2.51M-54.6% | $2.39M-99.5% | $1.43M-99.8% | $1.89M-99.7% | $5.54M-99.2% | ||
| —— | —— | —— | —— | —— | ||
| -$226.25M-30.5% | -$213.66M-33.8% | -$181.67M-13.8% | -$188.48M-53.3% | -$173.35M-43.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Celldex Therapeutics generate?
- Celldex Therapeutics (CLDX) generated -$222.2M in operating cash flow over the trailing twelve months.
- What is Celldex Therapeutics's free cash flow?
- After $4.1M of capital expenditures, Celldex Therapeutics's free cash flow was -$226.2M over the trailing twelve months, down 30.5% year over year.
- Where does Celldex Therapeutics's cash flow data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
